Corbus outlines U.S. approval path for lead drug

(Reuters) - Corbus Pharmaceuticals said on Wednesday that the U.S. health regulator only requires one positive pivotal late-stage study to support a marketing application for its lead experimental therapy as a treatment for scleroderma.